Investigational Drug Information for Azimilide

What is the drug development status for Azimilide?

Azimilide is an investigational drug.

There have been 8 clinical trials for Azimilide. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1^st 2001.

The most common disease conditions in clinical trials are Atrial Fibrillation, Arrhythmias, Cardiac, and Heart Diseases. The leading clinical trial sponsors are Forest Laboratories, Warner Chilcott, and [disabled in preview].

Summary for Azimilide

US Patents	0
International Patents	0
US Patent Applications	1,118
WIPO Patent Applications	423
Japanese Patent Applications	115
Clinical Trial Progress	Phase 3 (2001-09-01)
Vendors	32

Recent Clinical Trials for Azimilide

Title	Sponsor	Phase
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)	Forest Laboratories	Phase 3
Effect of Azimilide Dihydrochloride on Renal Function	Forest Laboratories	Phase 1
Effect of Azimilide Dihydrochloride on Renal Function	Warner Chilcott	Phase 1

See all Azimilide clinical trials

Clinical Trial Summary for Azimilide

Top disease conditions for Azimilide

Top clinical trial sponsors for Azimilide

See all Azimilide clinical trials

US Patents for Azimilide

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration

Azimilide Development Update, Patent Position and Market Projection

Last updated: September 24, 2026

Azimilide is a discontinued investigational class III antiarrhythmic. Procter & Gamble advanced azimilide into late-stage clinical development for atrial fibrillation, atrial flutter and ventricular arrhythmias, but the drug did not obtain FDA approval. It has no active U.S. commercial market, no Orange Book listing, no approved generic pathway and no biosimilar relevance. The base-case 2025-2030 revenue projection is therefore $0.

What is the current development status of azimilide?

Azimilide dihydrochloride is an oral potassium-channel blocker designed to prolong cardiac repolarization and increase the atrial and ventricular refractory period. It was evaluated as a once-daily treatment for:

• Maintenance of sinus rhythm after cardioversion
• Prevention of recurrent atrial fibrillation and atrial flutter
• Reduction of ventricular tachyarrhythmias and implantable cardioverter-defibrillator interventions

Azimilide reached Phase III development but was not approved by the FDA, European Medicines Agency or other major regulatory agencies. Public clinical-development records identify azimilide as discontinued rather than active or partnered in a registrational program. ClinicalTrials.gov lists historical azimilide studies, but no current pivotal development program is evident.[1]

The principal development issue was the benefit-risk profile. Azimilide produced antiarrhythmic activity, but QT-interval prolongation and proarrhythmic risk limited its commercial viability. The drug also entered a market in which amiodarone, sotalol, dofetilide, catheter ablation and implantable devices already occupied established treatment positions.

What diseases was azimilide intended to treat?

The primary target indications were atrial fibrillation and atrial flutter. The drug was also tested in patients with implantable cardioverter-defibrillators and structural heart disease to determine whether it could reduce recurrent ventricular tachycardia and shocks.

Azimilide was not developed as an anticoagulant. It would not have replaced warfarin or direct oral anticoagulants for stroke prevention in atrial fibrillation.

What did the azimilide clinical program show?

Atrial fibrillation and atrial flutter

Clinical studies reported improved maintenance of sinus rhythm compared with placebo, with evidence of dose-related activity. The clinical value was constrained by:

• QT prolongation
• Torsades de pointes risk
• Need for electrocardiographic monitoring
• Limited evidence of a mortality benefit
• Competition from established antiarrhythmics and ablation

The atrial-fibrillation data were not sufficient to support a durable regulatory case. In antiarrhythmic development, recurrence reduction alone is often inadequate when the treatment can increase ventricular arrhythmia risk.

Ventricular arrhythmias and ICD patients

The SHIELD program evaluated azimilide in patients with implantable cardioverter-defibrillators. The study reported reductions in the frequency of ventricular tachyarrhythmia events and ICD therapies at certain doses. Those findings did not establish an acceptable overall clinical profile for approval.[2]

The commercial opportunity was also narrower than a conventional atrial-fibrillation indication. ICD patients represent a specialized population, and an antiarrhythmic intended to reduce shocks must demonstrate meaningful clinical benefit without increasing mortality or serious proarrhythmia.

Safety profile

Azimilide’s main safety liability was delayed ventricular repolarization. The pharmacology created a risk of excessive QT prolongation and torsades de pointes, particularly in patients with:

• Structural heart disease
• Reduced left-ventricular function
• Electrolyte abnormalities
• Renal or hepatic impairment
• Concomitant QT-prolonging medicines

This liability is material because the intended patient population already has a high baseline risk of ventricular arrhythmia and sudden cardiac death.

When did azimilide lose exclusivity and regulatory momentum?

Azimilide did not lose market exclusivity through ordinary post-approval generic erosion. It failed before obtaining a U.S. marketing approval. As a result, the more important commercial event was discontinuation of development, not patent expiry.

Milestone	Status
Discovery and early development	Completed
Phase II testing	Completed
Phase III atrial-fibrillation and ventricular-arrhythmia studies	Completed
FDA approval	Not obtained
U.S. NDA commercial launch	None
Orange Book listing	None
Authorized generic	None
Biosimilar pathway	Not applicable
Current active development	No public active program identified

The original compound and formulation patent families may have expired or become commercially irrelevant because no approved product remained to support regulatory exclusivity. Patent expiry alone would not create an immediate generic market. A generic applicant normally needs an approved reference listed drug and an FDA-approved abbreviated new drug application.

What is the Orange Book status of azimilide?

Azimilide has no FDA Orange Book reference listed drug status because the FDA has not approved an azimilide product. The absence of an Orange Book listing has several consequences:

1. There is no listed U.S. drug-substance or formulation patent blocking an ANDA.
2. There is no FDA-established reference product for conventional generic substitution.
3. There is no Paragraph IV litigation framework comparable to an approved branded drug.
4. There is no Hatch-Waxman market exclusivity period currently protecting a marketed azimilide product.

The absence of an Orange Book listing does not mean that all historical patent rights disappeared. It means that those rights are not connected to an approved reference product in the Orange Book.

Which companies are challenging azimilide patents?

No meaningful current Paragraph IV challenge is publicly associated with azimilide. The reason is commercial rather than legal: azimilide has no approved U.S. reference product generating a conventional generic opportunity.

Historical patent ownership was associated with Procter & Gamble and its pharmaceutical operations. Public records do not show an active, material patent dispute involving azimilide that would affect near-term market entry.

What patent protection covered azimilide?

Historical protection likely included a combination of:

• Composition-of-matter claims
• Pharmaceutical salt claims, including the dihydrochloride form
• Oral dosage-form claims
• Methods of treating atrial fibrillation or ventricular arrhythmias
• Dosing and administration claims

The commercial importance of those claims has declined because the drug never reached approval. Method-of-use claims would also have faced substantial enforcement limitations without an approved commercial product and without a defined generic entry event.

A current freedom-to-operate assessment would require a patent-family review across the United States, Europe, Japan and other target markets. The available regulatory record supports the conclusion that historical patent protection is not creating a live commercial barrier today.

What formulation patents protect azimilide?

Azimilide was primarily developed as an oral systemic drug. The relevant formulation concepts would have included tablets or capsules containing azimilide or azimilide dihydrochloride, along with conventional excipients and dosage strengths.

No approved long-acting injectable, implantable, transdermal or inhaled azimilide formulation is publicly established. There is also no commercially validated formulation technology comparable to a proprietary delivery platform.

Formulation patents would have limited value in the current market unless a sponsor revived the compound with a differentiated product, such as:

• A lower-exposure formulation intended to reduce QT prolongation
• A modified-release tablet
• A combination product
• A formulation targeted at ICD patients
• A pharmacogenetically selected patient population

Such a program would require new clinical evidence rather than reliance on historical formulation data.

Is azimilide a biosimilar or generic opportunity?

Azimilide is a small molecule, so biosimilar rules do not apply. A future developer would pursue a conventional generic or full new-drug pathway, depending on whether an approved reference product exists and whether the proposed product matched an accepted regulatory standard.

Because azimilide was not approved in the United States, an entrant could face a difficult regulatory choice:

• File a full NDA supported by new safety and efficacy data
• Seek an abbreviated pathway if a suitable reference product and legal basis existed
• Develop the molecule in a new indication or formulation

The first option would involve substantial clinical risk. The second is commercially uncertain because no U.S. reference-listed drug is available. The third would require differentiation against safer and better-established therapies.

How strong is the azimilide patent estate?

The current commercial strength of the azimilide patent estate is low.

Patent-estate factor	Assessment
Composition-of-matter protection	Historical, likely expired or commercially exhausted
Formulation protection	Limited commercial relevance
Method-of-use protection	Weak without an approved product
Regulatory exclusivity	None currently available
Orange Book leverage	None
Litigation leverage	Low
Manufacturing complexity	Moderate, but not a decisive barrier
Competitive differentiation	Poor without a redesigned safety profile
Overall current strength	Low

The chemistry is not generally viewed as an insurmountable manufacturing challenge. The principal barrier is clinical and regulatory risk, especially QT prolongation and proarrhythmia. A new sponsor would need to solve the safety problem or identify a narrowly defined population in which the benefit-risk balance is favorable.

What licensing deals involve azimilide?

Procter & Gamble was the principal company associated with azimilide’s clinical development. No current licensing transaction or active commercial partnership is publicly established.

A future licensing deal would probably be structured around rights to historical data, patents and clinical know-how rather than an existing revenue stream. The value of those assets would be discounted heavily because:

• The drug has no approval
• There is no current sales base
• The clinical program is historical
• The target market has changed
• Competing therapies are entrenched
• A new sponsor would assume substantial regulatory risk

What is the azimilide market projection for 2025-2030?

The base-case forecast is zero revenue because azimilide is not marketed and has no active regulatory development program.

Scenario	Probability assessment	2030 revenue outlook
No redevelopment	Highest	$0
Academic or noncommercial redevelopment	Low	Minimal or no revenue
Revival for atrial fibrillation	Very low	Potentially $50 million-$150 million peak sales
Revival for ICD or ventricular-arrhythmia use	Very low	Potentially below $100 million peak sales
Successful global relaunch	Remote	Highly uncertain

The upside ranges are scenario values, not a base-case forecast. They assume a sponsor would obtain new funding, establish a current clinical and regulatory strategy, demonstrate an acceptable safety profile and differentiate azimilide against generic antiarrhythmics and catheter ablation.

A revived program would likely require at least several years of clinical work and could require hundreds of millions of dollars before approval. The time from redevelopment to launch could exceed seven years. The expected risk-adjusted value remains low.

How does azimilide compare with competing antiarrhythmics?

Drug or therapy	Regulatory status	Main advantage	Main limitation compared with azimilide
Amiodarone	Approved	Strong efficacy across arrhythmias	Organ toxicity and monitoring
Sotalol	Approved	Established use and generic availability	QT prolongation and renal dosing
Dofetilide	Approved	Atrial-fibrillation efficacy	Mandatory initiation monitoring and QT risk
Dronedarone	Approved	Lower systemic toxicity than amiodarone	Lower efficacy and heart-failure restrictions
Catheter ablation	Established procedure	Durable rhythm-control option in selected patients	Procedural risk and resource requirements
Azimilide	Not approved	Historical once-daily antiarrhythmic activity	QT risk, no approval and no commercial access

Azimilide would enter a price-sensitive market dominated by generic drugs and procedural alternatives. A once-daily schedule alone would not provide sufficient differentiation.

What generic launch risks exist for azimilide?

A conventional generic launch is unlikely in the near term. The main risks are:

• No approved U.S. reference product
• No current Orange Book listing
• Lack of regulatory exclusivity
• Historical clinical data that may not satisfy current standards
• Need to address QT and torsades risk
• Limited physician demand for a discontinued compound
• Competition from inexpensive generic alternatives

The more credible commercial pathway would be redevelopment as a new product, not a simple generic launch.

What manufacturing and intellectual-property barriers remain?

Azimilide manufacturing is likely technically manageable for an experienced pharmaceutical manufacturer. The difficult barriers are:

1. Demonstrating reproducible active-ingredient quality.
2. Establishing impurity and polymorph controls.
3. Validating the dihydrochloride salt and oral dosage form.
4. Reconstructing or updating clinical safety data.
5. Establishing a modern risk-management plan for QT prolongation.
6. Securing enforceable claims around a differentiated formulation or population.

Manufacturing know-how may provide trade-secret value, but it is unlikely to create a durable market barrier without regulatory approval and meaningful clinical differentiation.

Key Takeaways

• Azimilide is a discontinued Phase III investigational antiarrhythmic.
• It was not approved by the FDA and has no U.S. commercial product.
• It has no Orange Book listing, Paragraph IV litigation or biosimilar pathway.
• The primary development limitation was QT prolongation and proarrhythmic risk.
• Historical patent protection does not create a material current commercial moat.
• The 2025-2030 base-case revenue forecast is $0.
• Redevelopment would require a new clinical strategy, substantial capital and a differentiated safety profile.
• A generic launch is less realistic than a full redevelopment or new-indication program.

FAQs

Could azimilide still be approved in the United States?

Only through a new sponsor-led regulatory program supported by current clinical evidence. Historical Phase III data would not by themselves establish a modern approval basis.

Does azimilide have an FDA-approved generic?

No. There is no approved azimilide generic and no approved U.S. reference product.

Is azimilide safer than amiodarone?

The available development history does not establish that azimilide has a superior overall safety profile. Azimilide’s QT and torsades risk was a central development concern, while amiodarone has a different profile dominated by chronic extracardiac toxicities.

Could azimilide be repurposed for implantable cardioverter-defibrillator patients?

The historical ICD program provides a potential scientific rationale, but a new trial would be required. The sponsor would need to show that reduced ICD therapies translate into meaningful clinical benefit without excess mortality or proarrhythmia.

What is the investment case for azimilide?

The investment case is weak under current conditions. The asset has no revenue, no approval, no active commercial sponsor and substantial safety-related development risk. Its value would depend almost entirely on acquiring rights cheaply and demonstrating a materially improved therapeutic profile.

References

1. ClinicalTrials.gov. (n.d.). Studies of azimilide hydrochloride in cardiac arrhythmias. U.S. National Library of Medicine. https://clinicaltrials.gov/
2. Hohnloser, S. H., Dorian, P., Roberts, R., Gent, M., Israel, C. W., Mewis, C., & SHIELD Investigators. (2004). Effect of azimilide on survival and arrhythmia recurrence in patients with implantable cardioverter-defibrillators. Circulation.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/